CN101890022B - 一种头孢哌酮钠他唑巴坦钠药物组合物脂质体注射剂 - Google Patents
一种头孢哌酮钠他唑巴坦钠药物组合物脂质体注射剂 Download PDFInfo
- Publication number
- CN101890022B CN101890022B CN2010102391660A CN201010239166A CN101890022B CN 101890022 B CN101890022 B CN 101890022B CN 2010102391660 A CN2010102391660 A CN 2010102391660A CN 201010239166 A CN201010239166 A CN 201010239166A CN 101890022 B CN101890022 B CN 101890022B
- Authority
- CN
- China
- Prior art keywords
- sodium
- hours
- tazobactam
- cefoperazone
- warming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 46
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 title claims abstract description 37
- 229960002417 cefoperazone sodium Drugs 0.000 title claims abstract description 37
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960000373 tazobactam sodium Drugs 0.000 title claims abstract description 31
- 238000002347 injection Methods 0.000 title claims abstract description 28
- 239000007924 injection Substances 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000012528 membrane Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 20
- 238000010792 warming Methods 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000004821 distillation Methods 0.000 claims description 12
- 229960003865 tazobactam Drugs 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 5
- 239000000337 buffer salt Substances 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- -1 myristoyl lecithin Chemical compound 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- 235000010265 sodium sulphite Nutrition 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 238000004945 emulsification Methods 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 26
- 238000005516 engineering process Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229960004682 cefoperazone Drugs 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960000614 sulbactam sodium Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102391660A CN101890022B (zh) | 2010-07-29 | 2010-07-29 | 一种头孢哌酮钠他唑巴坦钠药物组合物脂质体注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102391660A CN101890022B (zh) | 2010-07-29 | 2010-07-29 | 一种头孢哌酮钠他唑巴坦钠药物组合物脂质体注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101890022A CN101890022A (zh) | 2010-11-24 |
CN101890022B true CN101890022B (zh) | 2012-05-23 |
Family
ID=43099481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102391660A Expired - Fee Related CN101890022B (zh) | 2010-07-29 | 2010-07-29 | 一种头孢哌酮钠他唑巴坦钠药物组合物脂质体注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101890022B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048740B (zh) * | 2010-12-02 | 2012-06-13 | 郝志艳 | 头孢曲松钠他唑巴坦钠药物组合物脂质体注射剂 |
CN102512374A (zh) * | 2011-12-16 | 2012-06-27 | 苏州二叶制药有限公司 | 一种注射用头孢哌酮钠他唑巴坦钠的制备工艺 |
CN102614182B (zh) * | 2012-03-02 | 2013-05-29 | 海南美大制药有限公司 | 一种复方氨酚肾素药物组合物脂质体固体制剂 |
CN110772486A (zh) * | 2019-11-27 | 2020-02-11 | 苏州二叶制药有限公司 | 一种头孢哌酮组合制剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101036656A (zh) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | 稳定的头孢哌酮他唑巴坦药物复方制剂 |
CN101036654A (zh) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | 稳定的头孢哌酮舒巴坦药物复方制剂 |
CN101632677A (zh) * | 2009-08-26 | 2010-01-27 | 海南永田药物研究院有限公司 | 一种头孢哌酮钠他唑巴坦钠药物组合物混悬粉针剂及其新应用 |
-
2010
- 2010-07-29 CN CN2010102391660A patent/CN101890022B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101036656A (zh) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | 稳定的头孢哌酮他唑巴坦药物复方制剂 |
CN101036654A (zh) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | 稳定的头孢哌酮舒巴坦药物复方制剂 |
CN101632677A (zh) * | 2009-08-26 | 2010-01-27 | 海南永田药物研究院有限公司 | 一种头孢哌酮钠他唑巴坦钠药物组合物混悬粉针剂及其新应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101890022A (zh) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102144981B (zh) | 一种盐酸吉西他滨冻干粉针剂及其制备方法 | |
CN101596160B (zh) | 一种α-细辛脑混合胶束注射剂及其制备方法、应用及其冻干粉针制剂 | |
CN101890022B (zh) | 一种头孢哌酮钠他唑巴坦钠药物组合物脂质体注射剂 | |
CN103040770B (zh) | 一种诺卡沙星冻干粉针剂的制备方法 | |
CN101716149A (zh) | 一种新的前体药物制剂 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN104352454B (zh) | 注射用夫西地酸钠粉针剂药物组合物和制法 | |
CN110812334A (zh) | 一种注射用伏立康唑药物组合物及其制备方法 | |
CN101804051B (zh) | 一种阿莫西林钠克拉维酸钾药物组合物脂质体注射剂 | |
CN102481287B (zh) | 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法 | |
CN109432009A (zh) | 一种头孢匹胺钠脂质体及其制备方法和应用 | |
AU2013377601B2 (en) | Stable nocathiacin lyophilized powder injection agent | |
CN101890014B (zh) | 一种哌拉西林钠舒巴坦钠药物组合物脂质体注射剂 | |
CN103040855A (zh) | 一种磷酸氟达拉滨的药物组合物及其制备方法 | |
CN103494779B (zh) | 一种注射用炎琥宁粉针制剂及其制备方法 | |
CN101028250A (zh) | 藤黄酸脂质体及其冻干粉针剂与制备方法 | |
CN101804052B (zh) | 一种美洛西林钠舒巴坦钠药物组合物脂质体注射剂 | |
CN101890015B (zh) | 一种哌拉西林钠他唑巴坦钠药物组合物脂质体注射剂 | |
CN103735522B (zh) | 一种炎琥宁冻干粉针及其制备方法 | |
CN102552923A (zh) | 包含左卡尼汀和辅酶q10的药物组合物及其制备方法 | |
CN102048740B (zh) | 头孢曲松钠他唑巴坦钠药物组合物脂质体注射剂 | |
CN107569508A (zh) | 一种治疗造血系统增殖性疾病的药用组合物 | |
CN105663060B (zh) | 一种去水卫矛醇脂质体冻干粉针剂及其制备方法 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN104352433A (zh) | 一种水包油型复方头孢唑啉纳米乳抗菌药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN LINGKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG MING Effective date: 20130724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130724 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd. Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601 Patentee before: Wang Ming |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20160729 |
|
CF01 | Termination of patent right due to non-payment of annual fee |